9-(3-phosphonylmethoxypropyl)adenine | 107021-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(3-phosphonylmethoxypropyl)adenine
• 英文别名: 9-(2-phosphonomethoxypropyl)adenine；3-(6-Aminopurin-9-yl)propoxymethylphosphonic acid
• CAS: 107021-13-6
• 化学式: C₉H₁₄N₅O₄P
• 分子量: 287.215
• InChiKey: BKLZHVCAEBYXHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  136
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  sodium;3-(6-benzamidopurin-9-yl)propan-1-olate 生成 9-(3-phosphonylmethoxypropyl)adenine
  参考文献：
  名称：

  ROSENBERG, IVAN;HOLY, ANTONIN;MASOJIDKOVA, MILENA, COLLECT. CZECHOSL. CHEM. COMMUN., 53,(1988) N1B, C. P2753-2777

  摘要：

  DOI：

文献信息

• Pharmacologically active agents containing esterified phosphonates and methods for use thereof
  申请人：Hostetler Y. Karl

  公开号：US20050192246A1

  公开（公告）日：2005-09-01

  Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates.

  提供了用于治疗、预防或改善与病毒感染、细胞增殖和骨代谢相关的各种医学疾病的化合物和组合物。本文提供的化合物是磷酸酯的烷基酯。
• Acyclic purine phosphonate analogs as antiviral agents. Synthesis and structure-activity relationships
  作者：Choung Un Kim、Bing Yu Luh、Peter F. Misco、Joanne J. Bronson、Michael J. M. Hitchcock、Ismail Ghazzouli、John C. Martin

  DOI：10.1021/jm00166a019

  日期：1990.4

  observed by the bovine brain guanylate kinase. Since all isosteric analogues of PMEG (7-9) were not inhibitory against HSV-1 and HSV-2, the presence of the 3'-oxygen atom in the PME purines proved critical for anti-HSV activity. Introduction of the 1'-methyl group on the PMEG side chain significantly reduced its anti-HSV activity. Analogue 11, which is a mimic of the phosphate by incorporation of the alpha

  合成了一系列9-（膦酰基烷基）嘌呤，它们是9- [2-（膦酰基甲氧基）乙基]嘌呤的类似物（鸟嘌呤，PMEG，1；腺嘌呤，PMEA，2）。测试了类似物对1型和2型单纯疱疹病毒（HSV-1和HSV-2），人巨细胞病毒（HCMV），罗氏鼠白血病病毒（R-MuLV）和1型人类免疫缺陷病毒（HIV-1）的活性）。随着烷基链长度的变化，嘌呤碱和膦酰基甲氧基官能团之间有两个碳原子，从而实现了最佳活性。尽管与PMEG的结构相似且pKa2值接近8，但牛脑鸟苷酸激酶未观察到8的磷酸化。由于所有PMEG的等距类似物（7-9）均不能抑制HSV-1和HSV-2，因此存在3' PME嘌呤中的-氧原子被证明对抗HSV活性至关重要。在PMEG侧链上引入1'-甲基会大大降低其抗HSV活性。通过掺入α，α-二氟碳来模拟磷酸盐的类似物11对HSV-1和HSV-2无效。这些结果表明，PME嘌呤的抗HSV活性的结构要求似乎非常严格。
• Synthesis Method For Improved Tenofovir Disoproxil Fumarate Using Ion-Exchange Resin And Method For Preparing Oral Dissolving Film Form Using The Same
  申请人：FIRSON

  公开号：US20170354668A1

  公开（公告）日：2017-12-14

  The present invention relates to a synthesis method of preventing the formation of impurities and byproducts in the synthesis of tenofovir disoproxil fumarate (Teno-DF) used as a medicine for hepatitis B and HIV treatment due to its function to promote bioactivities. In the synthesis method of the present invention, an ion-exchange resin (Dowex 50W hydrogen form, sulfonic acidic cation exchange resin) is used to enhance the yield and purity of the compound. The present invention also relates to a method of preparing an oral dissolving film dosage form in the manufacture of a medicine using the tenofovir compound with high purity obtained by the synthesis method of the present invention as an effective ingredient.

  本发明涉及一种合成方法，用于预防在合成用于治疗乙肝和艾滋病的替诺福韦二丙氧基富马酸盐（Teno-DF）的过程中形成杂质和副产物的方法。该化合物因其促进生物活性的功能而被用作药物。在本发明的合成方法中，使用一种离子交换树脂（Dowex 50W氢型，磺酸性阳离子交换树脂）来增强化合物的产率和纯度。本发明还涉及一种制备口溶膜剂型的方法，用于制造药物，使用本发明的合成方法获得的高纯度替诺福韦化合物作为有效成分。
• Phosphonate compounds
  申请人：Hostetler Y. Karl

  公开号：US20050176673A1

  公开（公告）日：2005-08-11

  The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

  本发明涉及膦酸盐化合物、含有它们的组合物、获得它们的方法，以及它们用于治疗多种医学疾病，例如骨质疏松症和其他骨代谢障碍、癌症、病毒感染等。
• PHOSPHONATE COMPOUNDS
  申请人：Hostetler Y. Karl

  公开号：US20080103115A1

  公开（公告）日：2008-05-01

  The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

  本发明涉及磷酸酯化合物、含有它们的组合物、制备它们的方法以及它们用于治疗各种医学疾病，例如骨质疏松症和其他骨代谢紊乱、癌症、病毒感染等。